Amivantamab and lazertinib in patients with EGFR-mutant non-small cell lung (NSCLC) after progression on osimertinib and platinum-based chemotherapy: Updated results from CHRYSALIS-2.

被引：0
|
作者：
Shu, Catherine A.
Goto, Koichi
Ohe, Yuichiro
Besse, Benjamin
Lee, Se-Hoon
Wang, Yongsheng
Griesinger, Frank
Yang, James Chih-Hsin
Felip, Enriqueta
Sanborn, Rachel E.
Caro, Reyes Bernabe
Curtin, Joshua C.
Chen, Jun
Mahoney, Janine M.
Trani, Leonardo
Bauml, Joshua Michael
Knoblauch, Roland Elmar
Thayu, Meena
Cho, Byoung Chul
机构：
[1] Columbia Univ, Med Ctr, New York, NY USA
[2] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
[3] Natl Canc Ctr, Tokyo, Japan
[4] Paris Sacaly Univ, Inst Gustave Roussy, Villejuif, France
[5] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Seoul, South Korea
[6] Sichuan Univ, West China Hosp, Inst Clin Trial Ctr, Chengdu, Peoples R China
[7] Sichuan Univ, West China Hosp, Canc Ctr, Chengdu, Peoples R China
[8] Carl von Ossietzky Univ Oldenburg, Pius Hosp, Oldenburg, Germany
[9] Natl Taiwan Univ, Canc Ctr, Taipei, Taiwan
[10] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Barcelona, Spain
[11] Earle A Chiles Res Inst, Providence Canc Inst, Portland, OR USA
[12] Hosp Univ Virgen Rocio, Inst Biomed Seville, Seville, Spain
[13] Janssen R&D, Spring House, PA USA
[14] Yonsei Univ, Yonsei Canc Ctr, Coll Med, Seoul, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9006
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Osimertinib versus gefitinib followed by osimertinib in patients with EGFR-mutant non-small cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE trial
    Masip, J. Remon
    Besse, B.
    Aix, S. Ponce
    Perez, A. Callejo
    Al-Rabi, K.
    Caro, R. Bernabe
    Greillier, L.
    Tarruella, M. Majem
    Aransay, N. Reguart
    Monnet, I.
    Cousin, S.
    Lopez, P. Garrido
    Robinet, G.
    Campelo, R. Garciaprime
    Flandin, A-C. Madroszyk
    Mazieres, J.
    Curcio, H.
    Pretzenbacher, Y.
    Dingemans, A-M. C.
    Dziadziuszko, R.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S35 - S35
  • [32] Osimertinib beyond Progression in Patients with EGFR Mutated Non-small Cell Lung Cancer (NSCLC) Receiving Frontline Osimertinib
    Benyounes, A.
    Cohen, A.
    Rossi, S. Diamond
    Cannon, T.
    Yacur, M.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S657 - S657
  • [33] Amivantamab plus lazertinib vs osimertinib in first-line EGFR-mutant advanced non-small cell lung cancer (NSCLC) with biomarkers of high-risk disease: A secondary analysis from the phase 3 MARIPOSA study
    Felip, Enriqueta
    Cho, Byoung Chul
    Gutierrez, Vanesa
    Alip, Adlinda
    Besse, Benjamin
    Lu, Shun
    Spira, Alexander I.
    Girard, Nicolas
    Califano, Raffaele
    Gadgeel, Shirish M.
    Yang, James Chih-Hsin
    Nogami, Naoyuki
    Azuma, Koichi
    Curtin, Joshua C.
    Zhang, Jiarui
    Panchal, Anesh
    Ennis, Mariah
    Sethi, Seema Niphadkar
    Bauml, Joshua Michael
    Lee, Se-Hoon
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [34] Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial
    Ahn, M. -J.
    Yang, J.
    Yu, H.
    Saka, H.
    Ramalingam, S.
    Goto, K.
    Kim, S. -W.
    Yang, L.
    Walding, A.
    Oxnard, G. R.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S115 - S115
  • [35] Real-world data of atezolizumab in combination with bevacizumab, and platinum-based chemotherapy for EGFR-mutant metastatic non-small cell lung cancer patients after failure of EGFR tyrosine kinase inhibitors
    Wu, S. G.
    Huang, Y. L.
    Ho, C. C.
    Liao, W. Y.
    Tsai, T. H.
    Yang, J. C. H.
    Shih, J. Y.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S57 - S57
  • [36] Local control of brain metastases with osimertinib alone in patients with EGFR-mutant non-small cell lung cancer
    Hui, Caressa
    Qu, Vera
    Wang, Jen-Yeu
    von Eyben, Rie
    Chang, Yu-Cheng
    Chiang, Po-Lin
    Liang, Chih-Hung
    Lu, Jen-Tang
    Li, Gordon
    Hayden-Gephart, Melanie
    Wakelee, Heather
    Neal, Joel
    Ramchandran, Kavitha
    Das, Millie
    Nagpal, Seema
    Soltys, Scott
    Myall, Nathaniel
    Pollom, Erqi
    JOURNAL OF NEURO-ONCOLOGY, 2022, 160 (01) : 233 - 240
  • [37] Local Control of Brain Metastases with Osimertinib Alone in Patients with EGFR-Mutant Non-Small Cell Lung Cancer
    Hui, C.
    Qu, V.
    Wang, J. Y.
    Von Eyben, R.
    Chang, Y. C.
    Chiang, P. L.
    Liang, C. H.
    Lin, J. Y.
    Lu, J. T.
    Li, G.
    Hayden, M.
    Myall, N.
    Soltys, S. G.
    Pollom, E.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : E54 - E55
  • [38] Local control of brain metastases with osimertinib alone in patients with EGFR-mutant non-small cell lung cancer
    Caressa Hui
    Vera Qu
    Jen-Yeu Wang
    Rie von Eyben
    Yu-Cheng Chang
    Po-Lin Chiang
    Chih-Hung Liang
    Jen-Tang Lu
    Gordon Li
    Melanie Hayden-Gephart
    Heather Wakelee
    Joel Neal
    Kavitha Ramchandran
    Millie Das
    Seema Nagpal
    Scott Soltys
    Nathaniel Myall
    Erqi Pollom
    Journal of Neuro-Oncology, 2022, 160 : 233 - 240
  • [39] Impact of sequential therapy with osimertinib on the overall survival in patients with EGFR-mutant non-small cell lung cancer
    Inomata, Minehiko
    Matsumoto, Masahiro
    Mizushima, Isami
    Hayashi, Kana
    Seto, Zenta
    Tokui, Kotaro
    Taka, Chihiro
    Okazawa, Seisuke
    Kambara, Kenta
    Imanishi, Shingo
    Miwa, Toshiro
    Hayashi, Ryuji
    Matsui, Shoko
    Tobe, Kazuyuki
    EGYPTIAN JOURNAL OF BRONCHOLOGY, 2022, 16 (01)
  • [40] Prognosticators of osimertinib treatment outcomes in patients with EGFR-mutant non-small cell lung cancer and leptomeningeal metastasis
    Chiang, Chi-Lu
    Ho, Hsiang-Ling
    Yeh, Yi-Chen
    Lee, Cheng-Chia
    Huang, Hsu-Ching
    Shen, Chia-, I
    Luo, Yung-Hung
    Chen, Yuh-Min
    Chiu, Chao-Hua
    Chou, Teh-Ying
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (01) : 5 - 14
12345